The Latest Analyst Ratings for Belite Bio
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 4 analysts have published bullish opinions on Belite Bio (NASDAQ:BLTE) stock. The average price target is $56.0, implying significant upside from the current price of $18.2. However, this average has decreased by 3.45% from the previous average price target of $58.00.
July 25, 2023 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Analysts have given bullish ratings to Belite Bio (NASDAQ:BLTE) with an average price target of $56.0, indicating a significant upside from the current price of $18.2. However, the average price target has decreased by 3.45% from the previous target of $58.00.
The bullish ratings from analysts indicate a positive outlook for Belite Bio. The average price target suggests a significant potential upside, which could attract investors and drive the stock price up. However, the decrease in the average price target could indicate a slightly less optimistic view compared to previous assessments.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100